Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health and Clearside Biomedical announced the U.S. commercial launch of XIPERE®, the first FDA-approved therapy for suprachoroidal injection, designed to treat macular edema associated with uveitis. This therapy aims to address a serious condition affecting approximately 300,000 Americans, which can lead to vision loss. Key features include targeted delivery through the proprietary SCS Microinjector®, providing higher bioavailability and lower side effects compared to traditional methods. Training for eye care professionals on administration techniques is highlighted as crucial for successful implementation.
Bausch Health Companies (NYSE/TSX: BHC) announced a study demonstrating that FDA-approved medications for opioid-induced constipation (OIC), particularly RELISTOR®, significantly reduce hospitalization rates and costs. Research published in Advances in Therapy showed a 64% lower chance of hospitalization for OIC patients treated with OIC-Rx compared to those who were not. Furthermore, patients treated with RELISTOR had a reduction of $781 in healthcare costs per emergency department encounter. The study highlights the potential healthcare benefits and cost-effectiveness of using RELISTOR in OIC management.
Solta Medical Corporation, a subsidiary of Bausch Health Companies Inc. (BHC), has appointed Gary Gemignani as Chief Financial Officer, effective March 28, 2022. Gemignani brings over 35 years of experience in finance, previously serving as CFO for various pharmaceutical firms. His extensive background is expected to support Solta as it prepares for a potential IPO following a public filing on February 8, 2022. The IPO will involve Solta’s common shares, pending market conditions and regulatory approvals.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced new analyses for its dermatology products IDP-126 Gel, DUOBRII®, and SILIQ® at the AAD Annual Meeting from March 25-29, 2022. The investigational IDP-126 Gel aims to treat moderate-to-severe acne and could become a first-in-class therapy if approved. DUOBRII® effectiveness for maintaining skin clearance was also highlighted. Additionally, the company introduced a JUBLIA® virtual reality experience to educate about onychomycosis, impacting 35 million people in the U.S. annually.
Bausch Health Companies (NYSE/TSX: BHC) announced participation in two upcoming investor conferences. The events include the Cowen & Co. 42nd Annual Health Care Conference on March 8, 2022, at 12:50 p.m. ET, and the Barclays Global Healthcare Conference on March 15, 2022, at 11:15 a.m. ET. Key executives participating include Joseph C. Papa, Sam Eldessouky, and Arthur J. Shannon. Live webcasts will be available on the company's Investor Relations page.
Bausch Health Companies (NYSE/TSX: BHC) announces the opening of applications for the 2022 Aspire Higher Scholarship program, targeting students affected by dermatologic conditions. The program, active since 2013, will award nine scholarships of up to $10,000 each to aid educational pursuits. Applicants must submit recommendations and an essay detailing their experiences. This initiative has granted 60 scholarships totaling $828,000 over the years. Applications are open until May 31, 2022, with recipients announced in summer 2022.
On March 1, 2022, Salix Pharmaceuticals, part of Bausch Health (NYSE: BHC), partnered with the Colon Cancer Coalition to promote colorectal cancer screening awareness. The initiative, known as the Faces of Blue campaign, will share patient stories to encourage screenings, especially following the U.S. Preventive Services Task Force's guideline lowering the screening age to 45. This change affects approximately 45 million Americans now eligible for early detection screenings. Salix aims to enhance education and outreach through new resources and social media partnerships.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced participation in the J.P. Morgan Global High Yield & Leveraged Finance Conference on March 1, 2022, at 9:15 a.m. ET. Key executives, including CFO Sam Eldessouky and SVP Arthur J. Shannon, will represent the company. Bausch Health focuses on improving health with a range of products in eye health, gastroenterology, and dermatology. The company's commitment to advancing global health and innovative solutions is highlighted.
Bausch Health reported its fourth-quarter and full-year 2021 financial results, revealing revenues of $2.196 billion for Q4 and $8.434 billion for the full year, up 5% from 2020. Despite a net income of $69 million in Q4, the company faced a full-year net loss of $948 million. Noteworthy achievements include the successful launch of four new products and progress in IPO preparations for Bausch + Lomb and Solta. However, cash generated from operations dropped significantly by 94% in Q4, emphasizing operational challenges.
Bausch Health Companies (NYSE/TSX: BHC) announced the U.S. launch of the OraFit™ custom clear aligner system on Feb. 22, 2022, aimed at correcting malocclusion. This system features a three-layer design with high-performance materials, providing a comfortable and aesthetically pleasing option for patients. With malocclusion affecting approximately 66% of individuals in the U.S., OraFit™ offers dentists a new solution that promotes patient acceptance and compliance. It also integrates a user-friendly online resource for dental professionals to streamline case submissions.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
